Does Emgality Cause Weight Gain?
Clinical trials for Emgality (galcanezumab), a CGRP inhibitor for migraine prevention, showed no consistent weight gain. In placebo-controlled studies, average weight changes were minimal—around 0.2-0.3 kg over 6 months for both Emgality and placebo groups, with no significant difference.[1][2] Post-marketing reports occasionally mention weight changes, but these are not established as causal and occur at low rates (less than 1%).[3]
What Do Real-World Patient Experiences Show?
User reviews on platforms like Drugs.com and WebMD report mixed results: about 10-15% of reviewers note weight gain (often 5-10 lbs over months), while others report weight loss or no change. Factors like migraine-related lifestyle shifts or concurrent medications may contribute more than the drug itself.[4][5] No large observational studies confirm a direct link.
How Does Emgality Compare to Other Migraine Preventives on Weight?
| Drug | Weight Effect in Trials |
|------|-------------------------|
| Emgality (galcanezumab) | Neutral (minimal change) [1] |
| Aimovig (erenumab) | Neutral to slight gain (<1 kg) [6] |
| Ajovy (fremanezumab) | Neutral [7] |
| Nurtec ODT (rimegepant, acute) | Neutral [8] |
| Topamax (topiramate) | Frequent loss (5-10% body weight) [9] |
| Beta-blockers (e.g., propranolol) | Possible gain [10] |
CGRP drugs like Emgality generally avoid the weight issues seen with older options like tricyclics or beta-blockers.
Why Might Someone Experience Weight Changes Anyway?
Indirect effects include reduced migraine frequency leading to better appetite or activity levels. Rare metabolic shifts or interactions (e.g., with antidepressants) could play a role, but Emgality's mechanism—blocking CGRP protein—doesn't target hunger or metabolism.[2] Track BMI and consult a doctor if gain exceeds 5% body weight.
When Should You Talk to Your Doctor About This?
If weight gain persists despite diet/exercise, rule out thyroid issues, fluid retention, or other meds. Emgality's label lists no weight-related warnings, but monitoring is standard for long-term use.[3]
Sources
[1]: Emgality Prescribing Information (FDA)
[2]: NEJM Trial on Galcanezumab
[3]: Drugs.com Emgality Side Effects
[4]: Drugs.com User Reviews
[5]: WebMD Reviews
[6]: Aimovig Label (FDA)
[7]: Ajovy Label (FDA)
[8]: Nurtec Label (FDA)
[9]: Topamax Label (FDA)
[10]: Propranolol Review (AHS Guidelines)